The Evaluation of COVID Medications’ Impact on the Liver Enzymes: A Study on Patients in Al-Ramadi Hospital, Iraq

Résumé fourni par la source

This research aims to evaluate the liver enzymes in patients who have recovered from COVID-19 compared to healthy controls. The sample included 69 COVID-19 survivors with liver failure, aged 26 to 66 years (mean age 47.61 ± 11.69). 67 healthy adults aged 19 to 62 years (mean age 36.33) were compared. Pearson correlation (with some differences from Spearman's method) was used to determine the relationship between liver failure and the drugs used during treatment (ceftriaxone, azithromycin, levofloxacin, and remdesivir). The results showed significant differences in ALT, AST, and ALP levels (p<0.001), between the two groups. In recovered patients, ALT is associated with ceftriaxone (R = 0.443, p<0.001) and remdesivir (R = 0.441, p<0.001). AST levels are similarly associated with ceftriaxone (R = 0.529, p<0.001), remdesivir (R = 0.455, p<0.001), and azithromycin (R = 0.366, p<0.001).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.